Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Determine the Efficacy and Safety of PD-1 in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Next Previous
Trial Profile

Phase II Study to Determine the Efficacy and Safety of PD-1 in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Sintilimab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Dec 2023 New trial record
  • 24 Oct 2023 Results (n=37; From May 4, 2020 to Aug 10, 2022) assessing the safety and efficacy of GP regimen in combination with immune checkpoint inhibitor sintilimab as neoadjuvant therapy for MIBC patients and the feasibility of the following selective bladder sparing surgery, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top